Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension
Yann Grobs(Institut universitaire de cardiologie et de pneumologie de Québec), Sébastien Bonnet(Institut universitaire de cardiologie et de pneumologie de Québec), Steeve Provencher(Institut universitaire de cardiologie et de pneumologie de Québec), Sarah‐Eve Lemay(SNC-Lavalin (Canada)), Charlotte Romanet(Canadian Heart Research Centre), Mark Orcholski, Sandra Breuils‐Bonnet, Olivier Boucherat, Roxane Paulin, Victoria Toro(Canadian Heart Research Centre), Valérie Nadeau, Ève Tremblay, Charifa Awada, Alice Bourgeois, Kana Shimauchi(Canadian Heart Research Centre)
Cited by 16
Related Papers
A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth
|Cancer Cell|2007|1.5k
Defining the clinical validity of genes reported to cause pulmonary arterial hypertension
|Genetics in Medicine|2023|73
Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension
|American Journal of Respiratory and Critical Care Medicine|2020|34
ATP citrate lyase drives vascular remodeling in systemic and pulmonary vascular diseases through metabolic and epigenetic changes
|Science Translational Medicine|2024|33